Lees A M, McCluskey M A, Lees R S
Atherosclerosis. 1976 Jul-Aug;24(1-2):129-40. doi: 10.1016/0021-9150(76)90070-8.
Twenty-five patinets with well defined Type ii hyperlipoproteinemia were treated with a divided 15 g daily dose of colestipol, a bile acid sequestrant, for periods of up to 20 months. The patients were divided into 3 groups: Those with no obvious sequelae, those with arcus corneae, xanthomas, and/or xanthelasmas only, and those with atherosclerotic complications. Colestipol lowered plasma cholesterol in all 3 groups, but reduced it to normal or near-normal levels in only 9 of the 25 patients (36%). The response of plasma triglycerides was highly varible; the mean for each group was elevated by the drug. Colestipol was well-tolerated and its effect did not diminish with time. It is a useful drug in the treatment of hypercholesterolemia.
25例确诊为Ⅱ型高脂蛋白血症的患者接受了每日15克的考来烯胺（一种胆汁酸螯合剂）分次剂量治疗，疗程长达20个月。患者被分为3组：无明显后遗症组、仅有角膜弓、黄色瘤和/或睑黄瘤组以及有动脉粥样硬化并发症组。考来烯胺降低了所有3组患者的血浆胆固醇水平，但在25例患者中只有9例（36%）降至正常或接近正常水平。血浆甘油三酯的反应变化很大；每组的平均值因药物而升高。考来烯胺耐受性良好，其效果不会随时间减弱。它是治疗高胆固醇血症的一种有用药物。
